Co-analysis of network pharmacology and metabolomics: revealing the mechanism of using mixed strains to produce multi-stage fermentation products of fresh blue honeysuckle (Lonicera caerulea L.) to against hyperlipidemia

网络药理学与代谢组学联合分析:揭示利用混合菌株生产新鲜蓝金银花(Lonicera caerulea L.)多阶段发酵产物对抗高脂血症的机制

阅读:1

Abstract

This study systematically investigated the molecular mechanism of the physicochemical properties, bioactive compound spectrum, and lipid-lowering activity of fermented Lonicera caerulea L. juice (FLJ) by sequential fermentation of compound lactic acid bacteria and yeast. The results indicated that compared to other methods, the sequential fermentation strategy (SFL-Y) could significantly enhance the levels of bioactive substances (flavonoids, SOD enzyme) and lipid-lowering activity. Using LC-MS techniques, 193 differential metabolites were detected after fermentation, including changes in 14 major chemical components such as organic acids, amino acids, and flavonoids. In addition, phenylpropanoid biosynthesis and linoleic acid metabolism were the core pathways in the SFL-Y fermentation process. Regarding lipid-lowering activity, network pharmacology and molecular docking validated the interaction between key metabolites (9,10-epoxylinoleic acid, 9,10-DHOME) and hyperlipidemia targets (CXCL8, IL1B, MAPK14), elucidating their molecular mechanisms of lipid-lowering. This study provides a theoretical basis for developing functional fermented beverages through microbial community synergy and metabolic regulation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。